Fig. 2: Pre-treatment of MSCs influences the HSPC migration and distribution in co-cultures.
From: Luspatercept restores SDF-1-mediated hematopoietic support by MDS-derived mesenchymal stromal cells
A After 1 week of co-culturing HSPCs derived from healthy donors on GDF-11/RAP-536 pre-treated MDS MSC layers, the fold change of CD45+ cell numbers compared to the untreated control layers was determined in the supernatant and the adherent fraction under the indicated treatment conditions. Error bars represent mean ± SD of the adherent fraction, ns p > 0.05, **p < 0.01, ***p < 0.001, and the supernatant fraction, ns p > 0.05, ++p < 0.01, N = 5, analyzed by two-way ANOVA with Tukey’s multiple comparisons test. B The migratory capacity of co-culture-derived HSPCs was analyzed in a Boyden chamber trans-well system. Error bars represent mean ± SD. ns p > 0.05, **p < 0.01, ***p < 0.001, N = 3 different co-culture experiments. Significance was assessed by one-way ANOVA with Tukey’s multiple comparisons test.
